Wellgistics Health Mid-Year 2026 Outlook Focuses on DelivMeds AI Transaction
Wellgistics Health provided a mid-year 2026 corporate outlook. The Company intends to focus on closing the recently announced DelivMeds AI transaction, continuing to drive quarter-over-quarter growth through its Wellgistics Pharmacy business unit, and supporting the continued progress in the three key aspects of the DelivMeds AI transaction: PharmacyChain progress, Medical Drones implementation and Health Lives Here launch scheduled for the third quarter of 2026. "The last two weeks have been transformative for the Company from a strategic direction, financial structure and funding standpoint," said Interim Co-CEO Gerald Commissiong. "With the reverse split that was required to maintain our NASDAQ listing now behind us, and with the support of holders of a majority of our common shares limiting the supply of common shares available to trade through the lock-up agreement announced last Thursday that leaves approximately 1.3 million shares available to trade based on the Company's current estimates, the Company is now positioned for significant growth in the months ahead. New shares from the financing will not be eligible for resale until they are issued in accordance with the transaction documents and either registered for resale under an effective registration statement or eligible for resale under Rule 144 or another applicable exemption, expected in the third quarter. We expect our previously announced joint venture with KareRx to continue to increase our monthly pharmacy sales and are looking forward to establishing new manufacturer relationships as a result of the DelivMeds AI business model. With an expeditious closing of the DelivMeds AI transaction squarely in focus, we believe the addition of the 'all-of-healthcare' smart contracts claims to our exclusive PharmacyChain blockchain intellectual property stack is poised to significantly expand the Company's relationship with DataVault AI by making it one of Wellgistics' largest shareholders while allowing us to apply the full power of our proprietary EinsteinRx artificial intelligence decision-making technology beyond our current pharmacy-only license. The recently announced QOLPOM IP acquisition, once closed, will allow us to immediately integrate biometric confirmation of a drug's pharmacodynamic effect to begin to objectively confirm prescription use adherence within the Health Lives Here consumer app that is targeted for launch at the 2026 Pro Football Hall of Fame game in Canton, OH in August, while also setting the stage for the coming disruption of the pharmaceuticals and medical supplies delivery sector with biometric confirmation-enabled medical drones. The Health Lives Here app itself is currently being optimized for that launch, with telemedicine, telelabs and telepharmacy features being added to its unique mental health AI technology in order to tailor coaching and regimen compliance messaging around which the app itself is centered to help patients reach and maintain their health goals. All of these innovations are being built for the launch of Tollo Health's proprietary nutraceutical products starting with Forzet, a proprietary medical food positioned as an adjunct to GLP-1 agonist drugs to help limit muscle loss. We know that next-generation GLP-1 agonist product candidates in the pipeline are already being positioned to help mitigate muscle loss, and we believe that given Forzet's mechanism of action it will further enhance those drugs' benefit to patients. We also intend to focus on the underserved areas of active viral infections with Galectovid and Long COVID with Tollovid. We believe strongly that the COVID pandemic catalyzed an already-emerging trend of Americans seeking non-pharmaceutical solutions to help improve and maintain healthy immune function, while building muscle. Tollo Health's best-in-breed product pipeline integrated with Wellgistics' pharmacist-led patient-engagement philosophy elevates that message, especially as part of an overall healthcare messaging paradigm being advanced together with NFL Alumni."
